Neuronetics Prepares for Market Launch of New Depression Therapy; Hires Peter Anastasiou as Vice President, Marketing

Apr 10, 2006, 01:00 ET from Neuronetics, Inc.

    MALVERN, Pa., April 10 /PRNewswire/ -- Neuronetics, Inc., a privately
 held medical device company and developer of therapeutic neuromodulation
 technology for depression, today announced that Mr. Peter Anastasiou has
 joined as Vice President, Marketing. Mr. Anastasiou will lead the Company's
 efforts to bring its therapeutic Transcranial Magnetic Stimulation (TMS)
 technology to market.
     Neuronetics' TMS Therapy(TM) is a non-invasive treatment for
 depression. It uses highly focused, pulsed magnetic fields to restore
 function in brain regions believed to be linked to depression. TMS Therapy
 is an outpatient procedure performed in a physician's office in about 30
 minutes daily for several consecutive weeks.
     Neuronetics recently completed a randomized, placebo-controlled
 clinical trial at 23 leading clinical research institutions throughout the
 U.S., Canada and Australia. It tested the efficacy and safety of TMS
 Therapy on more than 300 patients suffering from major depression who had
 not benefited from antidepressant medication therapy. The trial results
 will be presented at the American Psychiatric Association Meeting in
 Toronto, Canada on May 23, 2006.
     The selection of Mr. Anastasiou as Vice President of Marketing is a
 critical step in preparing Neuronetics for launching its TMS Therapy
 product line following regulatory clearance. He will lead a marketing team
 that works closely with psychiatrists using this advanced new therapy.
     "Peter brings a wealth of experience in marketing antidepressants and
 detailed knowledge of our key customers -- psychiatrists," said Bruce J.
 Shook, President and CEO of Neuronetics. "His leadership and experience
 will be a tremendous asset as we work to make TMS Therapy available for
 people struggling with major depression."
     "Depression afflicts nearly 20 million Americans annually and is a
 growing problem," said Mr. Anastasiou. "I firmly believe TMS Therapy can
 help a significant number of them and am excited about helping make it
 widely available."
     Mr. Anastasiou joins Neuronetics from Bristol-Myers Squibb where he
 spent three years and was a Director of the U.S. Marketing Team for
 Abilify(R), a leading antipsychotic medication. Prior to BMS, Mr.
 Anastasiou was at Eli Lilly for 11 years where his responsibilities
 included the market preparations for the launch of Cymbalta(R), Lilly's
 latest entry into the antidepressant marketplace. He earned an MBA degree
 from Indiana University and an undergraduate degree in Economics and
 Management from Albion College.
     About Neuronetics, Inc.
     Neuronetics, Inc. is a privately held medical device company focused on
 developing therapies for psychiatric and neurological disorders by using
 the energy in magnetic fields. Based in Malvern, PA, Neuronetics is the
 leader in the development of TMS Therapy, a completely non-invasive form of
 neuromodulation. For more information, visit
     TMS Therapy is investigational and is not yet commercially available in
 the U.S.
     TMS Therapy is a trademark of Neuronetics, Inc.
     Abilify and Cymbalta are registered trademarks of Otsuka Pharmaceutical
 Co, Ltd and Eli Lilly & Co., respectively.

SOURCE Neuronetics, Inc.